These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

170 related articles for article (PubMed ID: 29393086)

  • 1. Uric Acid: The Unknown Uremic Toxin.
    Treviño-Becerra A
    Contrib Nephrol; 2018; 192():25-33. PubMed ID: 29393086
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Comparison of renoprotective effects of febuxostat and allopurinol in hyperuricemic patients with chronic kidney disease.
    Lee JW; Lee KH
    Int Urol Nephrol; 2019 Mar; 51(3):467-473. PubMed ID: 30604229
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The Effect of Xanthine Oxidase Inhibitors on Blood Pressure and Renal Function.
    Bove M; Cicero AFG; Borghi C
    Curr Hypertens Rep; 2017 Oct; 19(12):95. PubMed ID: 29071435
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effectiveness of febuxostat in patients with allopurinol-refractory hyperuricemic chronic kidney disease
.
    Kwak CH; Sohn M; Han N; Cho YS; Kim YS; Oh JM
    Int J Clin Pharmacol Ther; 2018 Jul; 56(7):321-327. PubMed ID: 29750634
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Allopurinol Against Progression of Chronic Kidney Disease.
    Golmohammadi S; Almasi A; Manouchehri M; Omrani HR; Zandkarimi MR
    Iran J Kidney Dis; 2017 Jul; 11(4):286-293. PubMed ID: 28794291
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Comparison of febuxostat and allopurinol for hyperuricemia in cardiac surgery patients with chronic kidney disease (NU-FLASH trial for CKD).
    Sezai A; Soma M; Nakata K; Osaka S; Ishii Y; Yaoita H; Hata H; Shiono M
    J Cardiol; 2015 Oct; 66(4):298-303. PubMed ID: 25649025
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Time to target uric acid to retard CKD progression.
    Kumagai T; Ota T; Tamura Y; Chang WX; Shibata S; Uchida S
    Clin Exp Nephrol; 2017 Apr; 21(2):182-192. PubMed ID: 27339448
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The impact of serum uric acid reduction on renal function and blood pressure in chronic kidney disease patients with hyperuricemia.
    Tsuji T; Ohishi K; Takeda A; Goto D; Sato T; Ohashi N; Fujigaki Y; Kato A; Yasuda H
    Clin Exp Nephrol; 2018 Dec; 22(6):1300-1308. PubMed ID: 29700702
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Hyperuricemia, Hypertension, and Chronic Kidney Disease: an Emerging Association.
    Mallat SG; Al Kattar S; Tanios BY; Jurjus A
    Curr Hypertens Rep; 2016 Oct; 18(10):74. PubMed ID: 27696189
    [TBL] [Abstract][Full Text] [Related]  

  • 10. POSSIBILITIES OF RENOPROTECTION IN PATIENTS WITH CHRONIC KIDNEY DISEASE AND HYPERURICEMIA.
    Khimion LV; Burianov OA; Nayshtetik IM; Rotova SO; Smiyan SI; Danyliuk SV; Trofanchuk VV
    Wiad Lek; 2022; 75(5 pt 1):1059-1063. PubMed ID: 35758478
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Study of therapeutic efficacy of febuxostat in chronic kidney disease stage IIIA to stage VD.
    Sarvepalli PS; Fatima M; Quadri AK; Taher AR; Habeeb A; Amreen F; Parveen BN; Rajaram KG
    Saudi J Kidney Dis Transpl; 2018; 29(5):1050-1056. PubMed ID: 30381500
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A review investigating the effect of allopurinol on the progression of kidney disease in hyperuricemic patients with chronic kidney disease.
    Kabul S; Shepler B
    Clin Ther; 2012 Dec; 34(12):2293-6. PubMed ID: 23140758
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Treatment of Hyperuricemia in Chronic Kidney Disease.
    Ramirez-Sandoval JC; Madero M
    Contrib Nephrol; 2018; 192():135-146. PubMed ID: 29393124
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effects of Febuxostat on Oxidative Stress.
    Fukui T; Maruyama M; Yamauchi K; Yoshitaka S; Yasuda T; Abe Y
    Clin Ther; 2015 Jul; 37(7):1396-401. PubMed ID: 25913922
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Efficacy of Febuxostat for Slowing the GFR Decline in Patients With CKD and Asymptomatic Hyperuricemia: A 6-Month, Double-Blind, Randomized, Placebo-Controlled Trial.
    Sircar D; Chatterjee S; Waikhom R; Golay V; Raychaudhury A; Chatterjee S; Pandey R
    Am J Kidney Dis; 2015 Dec; 66(6):945-50. PubMed ID: 26233732
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Febuxostat is superior to allopurinol in delaying the progression of renal impairment in patients with chronic kidney disease and hyperuricemia.
    Zhang X; Wan D; Yang G; Peng Q; Wang X
    Int Urol Nephrol; 2019 Dec; 51(12):2273-2283. PubMed ID: 31646459
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Febuxostat improves endothelial function in hemodialysis patients with hyperuricemia: A randomized controlled study.
    Tsuruta Y; Kikuchi K; Tsuruta Y; Sasaki Y; Moriyama T; Itabashi M; Takei T; Uchida K; Akiba T; Tsuchiya K; Nitta K
    Hemodial Int; 2015 Oct; 19(4):514-20. PubMed ID: 25998500
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Urate-Lowering Therapy in Moderate to Severe Chronic Kidney Disease.
    Levy G; Shi JM; Cheetham TC; Rashid N
    Perm J; 2018; 22():17-142. PubMed ID: 30201087
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Uric Acid and Diabetic Nephropathy Risk.
    Mauer M; Doria A
    Contrib Nephrol; 2018; 192():103-109. PubMed ID: 29393137
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Preservation of renal function during gout treatment with febuxostat: a quantitative study.
    Whelton A; MacDonald PA; Chefo S; Gunawardhana L
    Postgrad Med; 2013 Jan; 125(1):106-14. PubMed ID: 23391676
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.